Sign in

CIK 0001439222

  • Large accelerated filer

AGIOS PHARMACEUTICALS, INC.

Sign in to watch
Ticker
AGIO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 617-649-8600
Business address
88 SIDNEY STREET, CAMBRIDGE, MA, 02139
Former names
AGIOS PHARMACEUTICALS INC
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$371,112
in 2 filings, $371K under 10b5-1 plans

Net −$371,112. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Gheuens Sarah −$371K Chief Medical Officer sold 15% of stake

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2018-03-14 Bowden Christopher Chief Medical Officer Option exercise +2,000 $35.16 $70K 2,881
2018-03-14 Bowden Christopher Chief Medical Officer Sale −1,700 $82.23 $140K 1,181
2018-03-14 Bowden Christopher Chief Medical Officer Sale −300 $82.90 $25K 881
2018-03-14 Bowden Christopher Chief Medical Officer Option exercise · Stock option (right to buy) −2,000 103,000
2018-03-05 Biller Scott Chief Scientific Officer Option exercise +3,000 $9.05 $27K 56,059
2018-03-05 Biller Scott Chief Scientific Officer Sale −400 $80.93 $32K 55,659
2018-03-05 Biller Scott Chief Scientific Officer Sale −400 $82.04 $33K 55,259
2018-03-05 Biller Scott Chief Scientific Officer Sale −1,100 $83.21 $92K 54,159
2018-03-05 Biller Scott Chief Scientific Officer Sale −1,100 $84.10 $93K 53,059
2018-03-05 Biller Scott Chief Scientific Officer Option exercise · Stock options (right to buy) −3,000 28,154
2018-03-01 Schenkein David P Chief Executive Officer Option exercise +13,000 $0.30 $4K 13,000
2018-03-01 Schenkein David P Chief Executive Officer Sale −2,915 $80.38 $234K 10,085
2018-03-01 Schenkein David P Chief Executive Officer Sale −10,085 $81.30 $820K 0
2018-03-01 Schenkein David P Chief Executive Officer Option exercise · Stock option (right to buy) −13,000 91,567
2018-02-26 Foster-Cheek Kaye I Director Option exercise +2,200 $47.33 $104K 2,200
2018-02-26 Foster-Cheek Kaye I Director Option exercise · Stock option (right to buy) −2,200 6,800
2018-02-22 Hoerter Steven L. Chief Commercial Officer Option exercise +2,050 $39.76 $82K 2,050
2018-02-22 Hoerter Steven L. Chief Commercial Officer Sale −2,050 $78.63 $161K 0
2018-02-22 Hoerter Steven L. Chief Commercial Officer Option exercise · Stock option (right to buy) −2,050 72,950
2018-02-16 Alenson Carman Principal Accounting Officer Grant or award · Stock option (right to buy) +9,480 9,480

Page 65 of 80 · 1,590 trades